A Quarterly Journal on HIV Prevention, Treatment and Politics SPRING[removed]acHIeVe

First Page		Document Content
Date: 2010-07-30 16:43:01 Microbiology HIV AIDS Microbicides for sexually transmitted diseases CAPRISA 004 Post-exposure prophylaxis Pre-exposure prophylaxis Division of Acquired Immunodeficiency Syndrome HIV/AIDS in China HIV/AIDS Medicine Health		A Quarterly Journal on HIV Prevention, Treatment and Politics SPRING[removed]acHIeVe Add to Reading List Source URL: img.thebody.com Download Document from Source Website File Size: 814,22 KB Share Document on Facebook

	Press Release: MayOmololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to a Pioneering Community Educator Who Brings the Voices of Community Members and Participants t DocID: 1gbaX - View Document
	FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx DocID: 1fD6y - View Document
	Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial SAVE THE DATE: Tuesday, 20 July 2010, 6.30pm-8.30pm An official satellite of XVII International AIDS Co DocID: 1deAN - View Document
	Results of the CAPRISA 004 trial of tenofovir gel Salim S Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director: CAPRISA DocID: 1ci9M - View Document
	What is CAPRISA 004? CAPRISA 004 was a phase IIb, two-arm, double-blind, randomised, placebo-controlled trial designed to assess the safety and effectiveness of the vaginal microbicide candidate 1% tenofovir gel for the DocID: 1bY73 - View Document